Effects of hydrocortisone-presensitized sugammadex on recovery from neuromuscular blockade induced by rocuronium: a rodent in vivo study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Hey-Ran | - |
dc.contributor.author | Yang, Hong Seuk | - |
dc.contributor.author | Choi, Jae-Moon | - |
dc.contributor.author | Park, Chungon | - |
dc.contributor.author | 인준용 | - |
dc.contributor.author | Kim, Yong Beom | - |
dc.date.accessioned | 2022-05-03T02:40:08Z | - |
dc.date.available | 2022-05-03T02:40:08Z | - |
dc.date.created | 2022-05-03 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 1975-5171 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84192 | - |
dc.description.abstract | Background: Sugammadex is a specific antagonist of aminosteroidal neuromuscular blocking agents with 1:1 binding to guest molecules. Sugammadex can also bind to other drugs having a steroid component in its chemical structure. In this in vivo experiment, we investigated the differences in the recovery of rocuronium-induced neuromuscular blockade using sugammadex pre-exposed with two different concentrations of hydrocortisone.Methods: The sciatic nerves and tibialis anterior muscles of 30 adult Sprague–Dawley rats were prepared for the experiment. The sciatic nerves were stimulated using a train-of-four (TOF) pattern with indirect supramaximal stimulation at 20 s intervals. After 15 min of stabilization, a 250 μg loading dose and 125 μg booster doses of rocuronium were serially administered until > 95% depression of the first twitch tension of TOF stimulation (T1) was confirmed. The study drugs were prepared by mixing sugamadex with the same volume of three different stock solutions (0.9% normal saline, 10 mg/ml hydrocortisone, and 100 mg/ml hydrocortisone). The recovery of rats from neuromuscular blockade was monitored by assessing T1 and the TOF ratio (TOFR) simultaneously until T1 was recovered to > 95% and TOFR to > 0.9.Results: In the group injected with sugammadex premixed with a high concentration of hydrocortisone, statistically significant intergroup differences were observed in the recovery progression of T1 and TOFR (P < 0.050).Conclusions: When sugammadex was pre-exposed to a high dose of hydrocortisone only, recovery from neuromuscular blockade was delayed. Delayed recovery from neuromuscular blockade is not always plausible when sugammadex is pre-exposed to steroidal drugs. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한마취통증의학회 | - |
dc.relation.isPartOf | Anesthesia and Pain Medicine | - |
dc.title | Effects of hydrocortisone-presensitized sugammadex on recovery from neuromuscular blockade induced by rocuronium: a rodent in vivo study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.17085/apm.21076 | - |
dc.identifier.bibliographicCitation | Anesthesia and Pain Medicine, v.17, no.2, pp.182 - 190 | - |
dc.identifier.kciid | ART002834411 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85165493297 | - |
dc.citation.endPage | 190 | - |
dc.citation.startPage | 182 | - |
dc.citation.title | Anesthesia and Pain Medicine | - |
dc.citation.volume | 17 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Park, Chungon | - |
dc.contributor.affiliatedAuthor | Kim, Yong Beom | - |
dc.subject.keywordAuthor | Hydrocortisone | - |
dc.subject.keywordAuthor | Neuromuscular blockade | - |
dc.subject.keywordAuthor | Neuromuscular blocking agent | - |
dc.subject.keywordAuthor | Neuromuscular junction | - |
dc.subject.keywordAuthor | Rocuronium | - |
dc.subject.keywordAuthor | Sugammadex. | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.